top of page

FDA approves expanded use of Novartis’ Ilaris to treat three rare periodic fever syndromes

Novartis has secured three new approvals from the US Food and Drug Administration (FDA) for the expanded use of Ilaris (canakinumab) to treat three rare types of Periodic Fever Syndromes.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page